` 0HNZ (Fagron NV) vs DAX Index Comparison - Alpha Spread

0HNZ
vs
D
DAX Index

Over the past 12 months, 0HNZ has outperformed DAX Index, delivering a return of +13% compared to DAX Index's +4% growth.

Stocks Performance
0HNZ vs DAX Index

Loading...
0HNZ
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
0HNZ vs DAX Index

Performance Gap Between 0HNZ and GDAXI
LOCKED
Unlock

Performance By Year
0HNZ vs DAX Index

Loading...
0HNZ
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Fagron NV vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Fagron NV
Glance View

Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.

0HNZ Intrinsic Value
LOCKED
Unlock
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett